Abstract
Background The incidence of infective endocarditis (IE) in pregnancy is rare (0.006%) with increasing prevalence during the opioid epidemic. IE in pregnancy is associated with high rates of maternal and fetal mortality and morbidity, and existing data on outcomes in pregnancy is limited to case reports and small studies. Our study compares the outcomes of pregnant patients with IE as compared to non-pregnant patients.
Methods Patients diagnosed with IE during pregnancy or 30 days post-partum between 2014-2021 were identified by ICD-9/10 codes. Pregnant cases were matched to a random sampling of non-pregnant reproductive-age female endocarditis patients in a 1:4 ratio. Demographic and clinical data was collected. Data was validated through chart review.
Results 180 patients with IE were identified for this cohort; 34 were pregnant or within 30 days post-partum at diagnosis. There were higher rates of hepatitis C and opioid maintenance therapy in the pregnant patients. Etiology of IE in pregnant patients was predominantly S. aureus (MSSA/MRSA) whereas non-pregnant woman had greater microbiological variation. We observed comparable rates of valve replacement (32.4% vs 29% p=0.84), 2-yr mortality (20.6% vs 17.8%, p =.>0.99), and ICU admission (61.8% vs 69.8%, p=0.414) in pregnant patients. There was a trend towards higher rates of PE (17.6% vs 7.5%, p=0.098), arrhythmia (17.6% vs 9.6%, p=0.222) among pregnant patients. There were high rates of IVDU relapse in both groups (>40%).
Conclusion We observed similar rates of valve replacement, 2-year mortality, and ICU admission in both pregnant and non-pregnant patients with IE. We observed a microbial predilection for S.aureus in pregnancy suggesting that the physiology of pregnancy may select for this microbiologic etiology. These results represent the largest single center retrospective review of IE in pregnancy and suggests that pregnancy may have increased morbidity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
n/a
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved via the University of Pittsburgh Medical Center Internal Review Board (STUDY21060177)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Data was obtained through chart review and did not use any public databases.
